Trial results for ONO / GS-4059, a potential blood cancer treatment, have been published by the University of Leicester and Leicester hospitals.

ONO / GS-4059 targets BTK, a protein essential for the survival and proliferation of tumour cells. It is being developed to treat chronic lymphocytic leukaemia and non-Hodgkin lymphoma patients who have resisted current chemotherapies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

"This drug has changed their lives. From desperate and tired, they are now leading a normal and really active life."

Around 90 patients, 28 from Leicester, were enrolled in UK and French trial centres.

The trial began in January 2012, and evaluated the new drug’s efficacy.

During the study, patients with chronic lymphocytic leukaemia showed the best response, without any notable toxicities.

See Also:

University of Leicester department of cancer studies Dr Harriet Walter said: "These patients were confronted with a cruel reality. They had failed multiple chemotherapy lines and there were no other treatment options available for them.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"This drug has changed their lives. From desperate and tired, they are now leading a normal and really active life."

The drug is expected to be trialled in combination with additional targeted agents, with recruitment likely begin soon in Leicester.

A team of scientists at the Haematological Research Institute are currently studying the functions of ONO / GS-4059, and exploring how to overcome potential resistance to the drug.

The trial was funded by ONO Pharmaceuticals.